Displaying 21 - 40 of 108
FTC Requires Generic Drug Marketers ANI Pharmaceuticals, Inc. and Novitium Pharma LLC to Divest Rights and Assets to Two Generic Products as Condition of Merger
FTC Requests Public Comment on Petition from Sartorius Stedim Biotech S.A. for Agency Approval of Its Acquisition of Chromatography Equipment Business of Novasep Process SAS
Statement of Commissioners Christine S. Wilson and Noah Joshua Phillips Regarding the Federal Trade Commission's Report to Congress on Rebate Walls
Statement of Acting Chairwoman Rebecca Kelly Slaughter Regarding the Federal Trade Commission’s Report to Congress on Rebate Walls
Statement of Commissioner Rohit Chopra Regarding the Commission's Report on Pharmacy Benefit Manager Rebate Walls
Federal Trade Commission Sends Report to Congress on Rebate Walls
Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson regarding the Multilateral Pharmaceutical Merger Task Force
Multilateral Pharmaceutical Merger Task Force Seeks Public Input
FTC Returns Nearly $60 Million to Those Suffering from Opioid Addiction Who Were Allegedly Overcharged in Suboxone Film Scheme
U.S. Court of Appeals for the Fifth Circuit Upholds FTC’s Opinion against Generic Pharmaceutical Company Impax Laboratories, LLC
FTC Announces Multilateral Working Group to Build a New Approach to Pharmaceutical Mergers
FTC Approves Final Order Imposing Conditions on Combination of Pfizer Inc.’s Upjohn and Mylan N.V.
Pfizer/Mylan, In the Matter of
Pharmaceutical companies Pfizer Inc. and Mylan N.V. have agreed to divest assets and abide by other conditions to settle Federal Trade Commission charges that the proposed combination of Upjohn Inc. and Mylan N.V. will harm current or future competition in ten generic drug markets. The FTC’s complaint alleges that the proposed combination would harm current U.S. competition in seven product markets by reducing the number of existing suppliers, and that it would harm future U.S. competition in three additional product markets. The proposed consent order requires divestitures in all 10 markets.
FTC Staff Issues FY 2017 Report on Branded Drug Firms' Patent Settlements with Generic Competitors
Statement of Commissioner Christine S. Wilson in the Matter of Pfizer Inc./Mylan N.V.
FTC Imposes Conditions on Combination of Pfizer Inc.’s Upjohn and Mylan N.V.
Displaying 21 - 40 of 108